Navigation Links
Rubicon Genomics Announces a Licensing Agreement With Abbott to Develop and Commercialize DNA Methylation Cancer Tests
Date:1/12/2009

ANN ARBOR, Mich., Jan. 12 /PRNewswire/ -- Rubicon Genomics today announced a licensing agreement with Abbott, which marks the achievement of significant milestones within their on-going Research and Option Agreement for development and commercialization of Rubicon MethylPlex(TM) methylation detection technology for the diagnosis and prognosis of cancer.

Under the terms of the agreement Abbott receives a non-exclusive license to MethylPlex for in vitro molecular diagnostics to detect the presence or risk of prostate, bladder and colon cancer for screening and non-screening indications. Abbott also obtains a non-exclusive license for non-screening applications with other diseases and options to colon cancer biomarkers developed in collaboration with Rubicon.

"This license is a significant validation of the MethylPlex technology as an effective, simple, automatable method for detecting cancer using DNA methylation in patient plasma," said James Koziarz, Acting President and CEO of Rubicon. Mr. Koziarz went on to say, "The collaboration between Rubicon and Abbott has been very productive with both parties making significant contributions towards development and commercialization of IVD products that employ MethylPlex biomarkers and assays. We look forward to continuing our joint efforts under our collaboration and developing leading edge products."

About Rubicon Genomics, Inc.

Rubicon, located in Ann Arbor, MI, is a pre-analytical platform company that has developed and commercialized reagents and kits to increase the analytical and clinical performance of analytical platforms including Q-PCR, microarrays, and next-gen sequencing. Its GenomePlex(TM), TransPlex(TM), and MethylPlex(TM) products achieve unbiased amplification and standardization of total DNA, total RNA, and methylated DNA. By producing highly pure DNA of uniform concentration and molecular weight these products increase the sensi
'/>"/>

SOURCE Rubicon Genomics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Nutrigenomics - Developing Personalized Diets for Disease Prevention - Is the Focus of a Special Issue of OMICS
2. Rosetta Genomics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
3. NeoGenomics Schedules Its Q3 2008 Earnings Release for November 6, 2008
4. UC San Diego to lead nationwide program in pharmacogenomics
5. NeoGenomics to Present at the Noble Financial Equity Conference
6. NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008
7. AutoGenomics, Inc. Files Registration Statement for Initial Public Offering
8. AutoGenomics INFINITI Analyzer Receives Artistic Design Award
9. AutoGenomics Receives a Key European Patent for HPV Detection
10. Genomics of Cardiovascular Disease: Current Clinical Applications
11. Navigenics Proposes Standards for Personal Genomics Services, Coupled With Prospective Outcomes Studies, to Safeguard Consumers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... Colic affects about one in five infants in the ... during the first several months after birth. Research into ... promise; however, the April 1, 2014 issue of the ... on a study, "Probiotics and Infant Colic," concluding that ... for infant colic did not reduce crying or ...
(Date:4/17/2014)... to ward off depression among retirees, particularly among those ... The Journals of Gerontology, Series B: Psychological ... " Internet Use and Depression Among Retired Older Adults ... authors report that Internet use reduced the probability of ... sample. , Late-life depression affects between 5 and ...
(Date:4/17/2014)... Massage therapy improves general blood flow and alleviates ... by researchers at the University of Illinois at ... of print in the Archives of Physical ... improved vascular function in people who had not ... regardless of their level of physical activity. , ...
(Date:4/17/2014)... Queen,s University Belfast,s Vice-Chancellor, Professor Patrick Johnston, whose work ... elected as a Fellow of the European Academy of ... is an independent advisory body of highly distinguished oncologists ... and suffering caused by cancer in Europe. , Professor ... Northern Ireland move from the bottom of the UK ...
(Date:4/16/2014)... HAMPTON, NJ (April 16, 2014): Celldex Therapeutics, Inc. ... Phase 1 study of CDX-1401 in solid tumors, including ... Translational Medicine (Vol 6 Issue 232). The data ... of clinical benefit in patients with very advanced cancers ...
Breaking Medicine News(10 mins):Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Internet use may cut retirees' depression 2Health News:Massage therapy improves circulation, eases muscle soreness 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4
... , SHENZHEN, China, Nov. ... http://www.beikebiotech.com ), China,s leading stem cell ... entered into an,agreement with Yokohama-based Biomaster Inc. ( ... technologies. Biomaster specializes in research,and commercialization of ...
... , COLUMBIA, S.C., Nov. 5 Companion Life Insurance ... facilitator to offer its dental policyholders preferred pricing on ... States. , Traveling abroad for credentialed dental care, also ... benefits. Prices at the international clinics average 60 to ...
... improvement, study finds, , THURSDAY, Nov. 5 (HealthDay News) -- ... make a good night,s sleep come more easily. , A ... that the odds of having disturbed sleep in the seven ... seven years before they stopped working. , Sleep improvements probably ...
... International Corporation (Nasdaq: PRXL ), a leading ... has established The Expert Office(TM) at PAREXEL. ... a single point of contact for clients to ... the Company,s leading medical, therapeutic area, regulatory, and ...
... ... published on GlucoStories.com , ... Pompano Beach, Fla. (PRWEB) November 5, 2009 --Today, American Diabetes Wholesale is asking ... will donate $3.00 for every story published on GlucoStories.com to diabetes organizations. The company’s ...
... ... for Thailand to become Asia,s medical hub is becoming a reality as Thailand continues to ... sector, ahead of the county,s GDP, the Tourism Authority of Thailand (TAT) and the Department ... lower medical treatments by 2010. , ...
Cached Medicine News:Health News:Beike Biotechnology Invests in Leading Japanese Regenerative Medicine Co., Biomaster Inc. 2Health News:Beike Biotechnology Invests in Leading Japanese Regenerative Medicine Co., Biomaster Inc. 3Health News:Beike Biotechnology Invests in Leading Japanese Regenerative Medicine Co., Biomaster Inc. 4Health News:Companion Life Adds Dental Tourism Option to Help Policyholders Save 2Health News:Companion Life Adds Dental Tourism Option to Help Policyholders Save 3Health News:Without Job Stress, Retirees Sleep Better 2Health News:PAREXEL Introduces The Expert Office(TM) -- Offering Enhanced Access to Comprehensive Expertise to Meet Strategic Partnering Needs 2Health News:PAREXEL Introduces The Expert Office(TM) -- Offering Enhanced Access to Comprehensive Expertise to Meet Strategic Partnering Needs 3Health News:PAREXEL Introduces The Expert Office(TM) -- Offering Enhanced Access to Comprehensive Expertise to Meet Strategic Partnering Needs 4Health News:PAREXEL Introduces The Expert Office(TM) -- Offering Enhanced Access to Comprehensive Expertise to Meet Strategic Partnering Needs 5Health News:GlucoStories Donation Campaign Aims to Raise Diabetes Awareness and Money for Diabetes Causes 2Health News:Thailand's Medical Tourism is Booming - Thailand on its Way to Become Asia's Medical Hub 2Health News:Thailand's Medical Tourism is Booming - Thailand on its Way to Become Asia's Medical Hub 3
(Date:1/15/2014)... Calif. , Jan. 15, 2014 Massachusetts ... (NASDAQ: AMGN ) announced today that ... discover and validate new therapeutic targets and develop ... chronic disorder that affects millions worldwide. The MGH-Broad-Amgen ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
... June 2, 2011 Goodwin Biotechnology, ... process development and GMP manufacturing of cell culture ... company focused on monoclonal antibody development with a ... discovery platform, announced a collaboration on the development ...
... Kendle (Nasdaq: KNDL ), a ... announced the appointment of Robert Shepard, MD, FACP, ...  Dr. Shepard is a leading authority on clinical ... of oncology research experience to Kendle. He will ...
Cached Medicine Technology:Goodwin Biotechnology Announces a Collaboration With Alethia Biotherapeutics 2Goodwin Biotechnology Announces a Collaboration With Alethia Biotherapeutics 3Kendle Appoints Robert Shepard, MD, FACP Executive Director, Oncology 2Kendle Appoints Robert Shepard, MD, FACP Executive Director, Oncology 3
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: